Tumor Characteristics in Patients With Paraneoplastic Neurological Syndromes (PNS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

980 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-02-01

Study Completion Date

2022-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Paraneoplastic neurological syndromes (PNS) are immune-mediated complications of cancer that can affect any part of the central or peripheral nervous system.

PNS occurs at the intersection between immune system and the tumor, where a combination of genetical and environmental factors may play a role.

Mechanisms leading to immune tolerance breakdown and autoimmunity in PNS remain largely unknown, and this reflects in an unsatisfactory repertoire of treatments available. Moreover, a better understanding of the biological mechanisms underlying PNS would allow a more precise identification of the modalities that permit PNS patients to have a better oncological prognosis than cancer patient without PNS, with obvious repercussions in clinical oncology.

To this effect, an extremely innovative approach involves directly exploring the tumoral tissue of patients suffering from specific PNS via genomic and transcriptomic analysis.

The study team hypothesizes that antigen ectopic expression by tumour cells may contribute to the generation of PNS.

In the present study, the investigators will analyze the salient features of tumors associated with PNS, namely the histological and immune cells infiltrate characteristics, their transcriptomic profile, and mutational status of involved antigens.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity

NCT06620913

CV2 Autoimmunity

ACTIVE_NOT_RECRUITING

Genetic and Molecular Characterization of Nervous System Lesions

NCT06314607

Brain Tumor Brain Lesion (General)

RECRUITING

Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma.

NCT06263361

Cerebral Lymphoma

RECRUITING

Prognosis Factors in Patients With Primary Central Nervous System Lymphoma

NCT05167630

PCNSL Survival Analysis

UNKNOWN

Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL)

NCT04253496

Primary Central Nervous System Lymphoma (PCNSL)

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Paraneoplastic Syndromes Neurologic Disorder Immune System and Related Disorders Tumor Genetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cancer patients with Paraneoplastic neurological syndromes

Cancer patients with Paraneoplastic neurological syndromes presenting various autoimmune anomalies:

* Anti-Hu also known as anti-Neuron specific cell Nuclear Antibodies (anti-ANNA1) (350 patients), uncommon form of brain inflammation associated with an underlying cancer
* anti-Yo (130 patients), antibody associated with paraneoplastic cerebellar degeneration
* anti-Ma2 (50 patients), antibody associated with paraneoplastic encephalitis
* anti-N-methyl-d-aspartate (NMDA) Receptor (350 patients), autoimmune disorder in which antibodies attack N-methyl-D-aspartate-type glutamate receptors
* anti-gamma-aminobutyric acid-B (GABAb) receptor (35 patients), autoimmune disorder in which antibodies attack gamma-aminobutyric acid-B receptors
* anti-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor (15 patients), autoimmune disorder in which antibodies attack alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors
* without antibodies (50 patients).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* presence of well characterized antibodies in serum or cerebrospinal fluid;
* histologically proven cancer with available tumour sample;
* Paraneoplastic neurological syndrome (PNS) diagnosis according to the international guidelines;
* Age: at least 18 years old.